Antifibrotic Efficacy of a Nintedanib–Peptide Conjugate and Diagnostic Potential of a Fluorescent Companion Probe Targeting αVβ6 Integrin in Idiopathic Pulmonary Fibrosis
Year: 2025
Type: article
Abstract: High Resolution Image Download MS PowerPoint Slide Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic pathology currently treated with two antifibrotic drugs, nintedanib and pirfenidone; however, more effective and safer cell-specific therapeutic agents are needed to overcome their limited efficacy and tolerability. αvβ6 integrin is a clinically validated fibrosis biomarker, and several αvβ6-targeted small molecules and positron emission tomography (PET) tracers have recently proven their therapeutic and diagnostic potential in IPF. Surprisingly, αvβ6-targeted and fibrosis-related drug conjugates are still lacking. Two molecular conjugates, namely the previously reported peptide–drug conjugate (PDC) 1 and the novel fluorescent probe 2, were developed here, where a αvβ6-targeted cyclopeptide is covalently linked to either nintedanib or the near-infrared (NIR) ZW800-1 fluorescent tag via robust linkers. Chemical synthesis of the two compounds, molecular docking studies of 1 in complex with αvβ6, mouse and human plasma stability measurement, binding affinity evaluation toward the isolated αvβ6 receptor, and in vitro human IPF-derived fibroblast cell internalization and antifibrotic studies were performed. Then, in vivo and ex vivo assessments of the antifibrotic efficacy of 1 and the diagnostic potential of 2 were carried out in a bleomycin (BLM)-induced lung fibrosis mouse model. Conjugate 1 demonstrated superior antifibrotic efficacy as compared to the separated peptide and drug components, and probe 2 specifically accumulated in the fibrotic lesions of mice lungs. The molecular conjugates 1 and 2 represent a promising theranostic couple for lung fibrosis and αvβ6-related pathologies and a useful proof-of-principle tool testifying how the simultaneous cell-targeted inhibition of multiple fibrosis-related receptors could be more impactful than the inhibition of one sole receptor.
Authors: Kelly Bugatti, Erica Ferrini, Margherita Restori, Costanza Bonfini, Melissa Marchese, Francesca Bianchini, Sara Tomassetti, Andrea Maurizio, Monica Baiula, Lucia Battistini, Enrico Marcantonio, Claudio Curti, Monica Civera, Laura Belvisi, Andrea Sartori, Franco F. Stellari, Franca Zanardi
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: G3161376858, G4216849998, G4881179561
OpenAlex ID: W4414281278
